Did you know Robert Haddad and Toni Choueiri, MD had a competitive streak? - Dana-Farber
Rob Gronkowski

#Cancer #Cancer Research #DanaFarberCancerInstitute #YouthFoundation #Clinic #NationalCancerInstitute #OncoDaily #Oncology

oncodaily.com/49490.html

Thank you Rob Gronkowski & Julian Edelman for a wonderful #pickleball game to benefit Dana-Farber The Jimmy Fund —we are in this together to beat Cancer !

Dana-Farber Robert Haddad Dana-Farber_GU Dana-FarberNews Pan-Mass Challenge G O L D I E.

We are getting ready Rob Gronkowski and Julian Edelman !!! We hope you are practicing too ! Let us cure Cancer together ! #pickelball

Dana-Farber Dana-Farber_GU Robert Haddad The Jimmy Fund G O L D I E. New England Patriots Dana-FarberNews

charity.pledgeit.org/f/ozX6IMVf7v

I’m teaming up with Robert Haddad to play pickeball against Rob Gronkowski and raise funds for cancer research for Dana-Farber !

Help us beat the Gronk (and Cancer!)

charity.pledgeit.org/f/ozX6IMVf7v

Out today--DC dysfunction in HNSCC antiPD1 resistance w/ a mechanistic role for CCL5 in enhancing DC function/ T cell priming. Congrats to Shin/Michi! Brigham and Women’s Department of Surgery Dana-Farber News Robert Haddad Glenn J. Hanna, M.D. Jonathan Schoenfeld tinyurl.com/686af9e9

First targeted therapy found safe and shows anti-tumor activity in patients with rare head and neck cancer. Dana-Farber's Robert Haddad, MD (@DrHaddadRobert) details the findings that were presented at #ESMO23 .

.Sue Yom, Robert Haddad, Nicole C. Schmitt, Angela L. Ferguson, and Barbara A. Burtness discussed 'Clinical Trials' in a plenary session today at the AACR-AHNS Head and Neck Cancer Conference.
#aacrAHNS23

This review discusses cisplatin ineligibility in pts with locally advanced #HNC #hncsm , summarizes the limited clinical evidence for adjuvant tx, & highlights ongoing clinical trials that have the potential to provide new tx options.
sciencedirect.com/science/articl…

1/ Results from #COSMIC -313 are out NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by Charles Swanton Andres Cervantes #ESMO22

Thread 🧵==>

nejm.org/doi/full/10.10…

TRIO Panel - Immunotherapy in H&N Cancer: What We Know, What We Think We Know and What We Really Don't. Join us tomorrow in Boston with the great ⁦Sana Karam, MD, PhD⁩ ⁦Lực Morris⁩ and ⁦Maie St. John⁩ ⁦COSM⁩ ⁦Triological Society⁩ . l.core-apps.com/cosm2023/event…

Finally out, our analysis from CONDOR/HAWK/EAGLE Tumor Mutational Burden as a Predictor of Survival With D+T in Recurrent Head and Neck Squamous Cell Carcinoma , also reporting on bTMB Robert Ferris, MD, PhD AstraZenecaUS Ezra Cohen AACR Ravi Uppaluri, MDPhD aacrjournals.org/clincancerres/…

Where’s the anomaly? . Matthew Davids, MD, MMSc #Madrid David Steensma, MD MM “intercepts” HN

Our paper on CT performance with ENE shows poor reproducibility among expert head/neck neuroradiologists and poor predictive value for histologic ENE rdcu.be/c42sc. Benjamin Kann, MD Sue Yom Dana-Farber News Brigham and Women’s Radiology Education Brigham and Women's Hospital Dr (Prof). Vijay Patil

Key question for trials is whether folks are comfortable randomizing to RT alone. The vote by Robert Haddad suggests only a quarter of us are willing but hopefully@more in the context of a trial for a cleaner answer

Pembrolizumab versus Cetuximab concurrent with radiotherapy in patient... sciencedirect.com/science/articl…
No difference in outcomes.We still need to define SOC for cis ineligible pts . what is yours ? Nabil Saba, MD David Sher Robert Ferris, MD, PhD Sean McBride

Out today Biomarkers predictive of response to pembrolizumab in head and neck cancer onlinelibrary.wiley.com/doi/10.1002/ca… we assess combined biomarker analysis from K012 and 055 Ravi Uppaluri, MDPhD Nabil Saba, MD Sana Karam, MD, PhD Ezra Cohen